The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours: ORIGINAL ARTICLE

Clinical and Experimental Immunology

Volumn 158, Issue 2, 2009, Pages 174-185

  Yang, H ^a   Cho, N H ^a,b   Seong, S Y ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Cancer immunotherapy; DC; HIV Tat; Mucin antigen 1; Protein transduction domain

Indexed keywords

ANTIGEN; EPITOPE; GAMMA INTERFERON; MUCIN 1; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL FUNCTION; CELLULAR IMMUNITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG CONJUGATION; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; WESTERN BLOTTING;

ANIMALS; CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; NEOPLASM PROTEINS; RECOMBINANT PROTEINS; SPLEEN; SURVIVAL ANALYSIS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 70349656486     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03997.x     Document Type: Article

References (45)

1. Hanisch FG. O-glycosylation of the mucin type. Biol Chem 2001 382 : 143 149.
2. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 2008 7 : 951 962.
3. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008 7 : 963 975.
4. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008 29 : 372 383.
5. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007 220 : 129 150.
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004 10 : 475 480.
7. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007 117 : 1195 1203.
8. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000 21 : 45 8.
9. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002 168 : 2393 2401.
10. Wang HY, Fu T, Wang G et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002 109 : 1463 1470.
11. Viehl CT, Tanaka Y, Chen T et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res Treat 2005 91 : 271 278.
12. Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 2003 33 : 850 860.
13. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007 179 : 2187 2194.
14. Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002 19 : 339 345.
15. Barratt-Boyes SM, Vlad A, Finn OJ. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 1999 5 : 1918 1924.
16. Yamamoto K, Ueno T, Kawaoka T et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005 25 : 3575 3579.
17. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995 155 : 4766 4774.
18. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 2000 18 : 2059 2071.
19. Kohlgraf KG, Gawron AJ, Higashi M et al. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 2004 53 : 1068 1084.
20. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 2001 91 : 385 392.
21. Apostolopoulos V, Pouniotis DS, van Maanen PJ et al. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine 2006 24 : 3191 3202.
22. Ninkovic T, Hanisch FG. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 2007 179 : 2380 2388.
23. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999 194 : 143 149.
24. Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003 109 : 300 307.
25. Usharauli D, Perez-Diez A, Matzinger P. The JAM test and its daughter P-JAM: simple tests of DNA fragmentation to measure cell death and stasis. Nat Protoc 2006 1 : 672 682.
26. Sarkar K, Bose A, Chakraborty K et al. Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage-mediated antigen presentation. Vaccine 2008 26 : 4352 4362.
27. Rughetti A, Pellicciotta I, Biffoni M et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 2005 174 : 7764 7772.
28. Maraskovsky E, Sjolander S, Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004 10 : 2879 2890.
29. Rieser C, Ramoner R, Holtl L et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 1999 63 : 151 159. (Pubitemid 30083819)
30. Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003 21 : 341 349.
31. Homma S, Matai K, Irie M, Ohno T, Kufe D, Toda G. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol 2003 38 : 989 994.
32. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003 52 : 387 395.
33. Kontani K, Taguchi O, Ozaki Y et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003 12 : 493 502.
34. Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 2008 68 : 6136 6144.
35. Ahmad R, Raina D, Trivedi V et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol 2007 9 : 1419 1427.
36. Carraway KL III., Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007 78 : 1 22.
37. Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem Soc Trans 2005 33 : 705 708.
38. Werdelin O, Meldal M, Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci USA 2002 99 : 9611 9613.
39. Glithero A, Tormo J, Haurum JS et al. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999 10 : 63 74.
40. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999 10 : 51 61.
41. Galli-Stampino L, Meinjohanns E, Frische K et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997 57 : 3214 3222.
42. Heukamp LC, van Hall T, Ossendorp F et al. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002 25 : 46 56.
43. Bae MY, Cho NH, Seong SY. Protective anti-tumor immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol 2009 157 : 128 138.
44. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 1998 58 : 2965 2968.
45. Mukherjee P, Madsen CS, Ginardi AR et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003 26 : 47 62.